Special Issue "Cancer Stem Cells"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2010).
2 Laboratory Director, UPMC Hematopoietic Stem Cell Laboratory, 5117 Centre Ave., Pittsburgh, PA 15213, USA
3 Deputy Director, UPCI Hematopoietic Stem Cell Transplantation Program, Hillman Cancer Center, 5117 Centre Ave., Suite 4.24c, Pittsburgh, PA 15213, USA
Interests: functional significance of T-cell activation markers; T-cell turnover in SIV infection; role of p-gp in resistance to immunosuppressive agents; immunologic consequences of autologous transplantation in systemic sclerosis; cancer stem cell
Interests: P-glycoprotein/ABC-transporters and drug interaction in T lymphocytes and beyond; tumorigenic stem cells; interaction of dormant tumor cells and regenerating tissue; MDR modulation and control by SHH pathway; lung immunology; strengths
Cancer treatment often must deal with the problem of recurrence. This leads to a question: are there specialized cells within a tumor that are relatively resistant to typical therapeutics and which possess the ability to reconstitute the malignancy? Put another way, do tumors contain “stem-like” cells with the properties of resistance and tumor reconstitution? Cancer stem cells (CSCs) have been defined as “cells within a tumor that possess the capacity to self-renew and to cause heterogeneous lineages of cancer cells that comprise the tumor” (see: http://stemcells.nih.gov/info/2006report/2006chapter9.htm). Putative CSCs have been identified for a variety of cancer types, and there are several theories to explain how CSCs develop and how they contribute to disease progression, including metastasis. This topic has profound implications for both the basic science of cancer biology, as well as for more applied studies of clinical and therapeutic relevance. Continued investigation of CSC biology will broaden our understanding of tumor initiation, progression, and metastasis, likely leading to novel preventive and therapeutic approaches against cancer. Therefore, we invite research and review papers in the broad field of cancer stem cells, including, but not limited to, topics relating CSCs to: cancer genetics, tumor biology, metastasis, cell signaling, diet and prevention, and pharmacological and genetic therapeutics. We look forward to your contributions.
Dr. Michael Bordonaro
Dr. Frank Pajonk